Patients with renal cell carcinoma (RCC) who received the first-line combination of avelumab and axitinib had longer progression-free survival (PFS) compared with those who received sunitinib, particularly those with PD-L1–positive tumours, according to findings of the phase III JAVELIN Renal 101* trial.
A combination therapy of nivolumab plus ipilimumab (NIVO + IPI) continues to confer survival benefit and durable response over 30 months of follow-up compared with sunitinib in patients with advanced renal cell carcinoma (RCC), according to updated results of CheckMate 214 presented at ASCO Genitourinary Cancers Symposium (GUCS) 2019.
Use of axitinib in the neoadjuvant setting appears to result in weight loss, with notable reductions in skeletal muscle and subcutaneous adipose tissue in patients with localized renal cell carcinoma, a recent study has shown.
Nivolumab plus ipilimumab significantly improves overall survival (OS) vs sunitinib in patients with intermediate- or poor-risk advanced renal cell carcinoma (RCC), according to results of the first-line CheckMate 214 study presented at the European Society for Medical Oncology (ESMO) 2017 Congress held in Madrid, Spain.
Some patients with metastatic renal cell carcinoma (mRCC) who have slow-growing disease can safely undergo active surveillance for months to years before starting systemic therapy, a small phase II study has shown.
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.
A recent study has shown that the short-term efficacy of tenofovir disoproxil fumarate (TDF) is superior to entecavir (ETV) for the treatment of acute-on-chronic-liver failure (ACLF) due to reactivation of chronic hepatitis B (CHB).